Phase III randomised trial| Volume 75, ISSUE 1, P9-17, April 2005

Download started.


Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial


      Background and purpose

      Unlike squamous carcinomas, breast adenocarcinoma may be as sensitive to fraction size as late dose-limiting normal tissues. If so, fewer larger fractions would be as safe and effective as regimens based on 2.0 Gy fractions. The first step is to test the effects of radiotherapy fractions >2.0 Gy on late normal tissue responses in the breast after tumour excision and radiotherapy for early breast cancer.

      Patients and methods

      One thousand four-hundred and ten women with T1-3 N0-1 M0 invasive breast cancer were randomised between 1986–98 into one of three radiotherapy regimens after local tumour excision of early stage breast cancer; 50 Gy in 25 fractions (F) vs two dose levels of a test schedule giving 39 or 42.9 Gy in 13 F over 5 weeks. Fraction sizes were 2.0, 3.0 and 3.3 Gy, respectively. The primary endpoint was late change in breast appearance compared to post-surgical appearance scored from annual photographs blinded to treatment allocation. Secondary endpoints included palpable breast induration (fibrosis) and ipsilateral tumour recurrence.


      After a minimum 5-year follow up, the risk of scoring any change in breast appearance after 50 Gy/25 F, 39 Gy/13 F and 42.9 Gy/13 F was 39.6, 30.3 and 45.7%, from which an α/β value of 3.6 Gy (95% CI 1.8–5.4) is estimated. The α/β value for palpable breast induration was 3.1 Gy (95% CI 1.8–4.4).


      An α/β value of around 3 Gy for late normal tissue changes in the breast is derived from the estimated equivalence of 41.6 Gy in 13 fractions and 50 Gy in 25 fractions over 5 weeks, in line with trial predictions.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bates T.
        Hypofractionation and the therapeutic ratio.
        Int J Radiat Oncol Biol Phys. 1989; 17: 443
        • Bentzen S.M.
        High-tech in radiation oncology: should there be a ceiling?.
        Int J Radiat Oncol Biol Phys. 2004; 58: 320-330
        • Bentzen S.M.
        • Baumann M.
        The linear-quadratic model in clinical practice.
        in: Steel G.G. Basic clinical radiobiology. Arnold, London2002: 134-146
        • Bentzen S.M.
        • Ruifrok A.C.
        • Thames H.D.
        Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy.
        Radiother Oncol. 1996; 38: 89-101
        • Brenner D.J.
        Hypofractionation for prostate cancer radiotherapy-what are the issues?.
        Int J Radiat Oncol Biol Phys. 2003; 57: 912-914
        • Cohen L.
        Radiotherapy in breast cancer I. The dose–time relationship theoretical considerations.
        Br J Radiol. 1952; 25: 636-642
        • Douglas B.G.
        Superfractionation: its rationale and anticipated benefits.
        Int J Radiat Oncol Biol Phys. 1982; 8: 1143-1153
        • Douglas B.G.
        • Castro J.R.
        Novel fractionation schemes and high linear energy transfer.
        Prog Exp Tumor Res. 1984; 28: 152-165
        • Fletcher G.H.
        Hypofractionation: lessons from complications.
        Radiother Oncol. 1991; 20: 10-15
        • Fowler J.F.
        The linear-quadratic formula and progress in fractionated radiotherapy.
        Br J Radiol. 1989; 62: 679-694
        • McKinna F.
        • Gothard L.
        • Ashley S.
        • et al.
        Selective avoidance of lymphatic radiotherapy in the conservative management of women with early breast cancer.
        Radiother Oncol. 1999; 52: 219-223
        • Owen J.R.
        • Yarnold J.R.
        • Ashton A.
        • et al.
        Fractionation sensitivity of the breast: results of a randomised trial.
        Eur J Oncol Suppl. 2003; 1: S9
        • Sneeuw K.C.
        • Aaronson N.K.
        • Yarnold J.R.
        • et al.
        Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 1. Comparison of patients' ratings, observers' ratings, and objective assessments.
        Radiother Oncol. 1992; 25: 153-159
        • Sneeuw K.C.
        • Aaronson N.K.
        • Yarnold J.R.
        • et al.
        Cosmetic and functional outcomes of breast conserving treatment for early stage breast cancer. 2. Relationship with psychosocial functioning.
        Radiother Oncol. 1992; 25: 160-166
        • Suit H.
        • Skates S.
        • Taghian A.
        • et al.
        Clinical implications of heterogeneity of tumor response to radiation therapy.
        Radiother Oncol. 1992; 25: 251-260
        • Thames H.D.
        • Bentzen S.M.
        • Turesson I.
        • et al.
        Time–dose factors in radiotherapy: a review of the human data.
        Radiother Oncol. 1990; 19: 219-235
        • Thames H.D.
        • Hendry J.H.
        • Moore J.V.
        • et al.
        The high steepness of dose-response curves for late-responding normal tissues.
        Radiother Oncol. 1989; 15: 49-53
        • Whelan T.
        • MacKenzie R.
        • Julian J.
        • et al.
        Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer.
        J Natl Cancer Inst. 2002; 94: 1143-1150
        • Winfield E.
        • Deighton A.
        • Venables K.
        • et al.
        Survey of UK breast radiotherapy techniques: background prior to the introduction of the quality assurance programme for the START (standardisation of radiotherapy) trial in breast cancer.
        Clin Oncol (R Coll Radiol). 2002; 14: 267-271
        • Winkelmann R.K.
        • Grado G.L.
        • Quimby S.R.
        • Connolly S.M.
        Pseudosclerodermatous panniculitis after irradiation: an unusual complication of megavoltage treatment of breast carcinoma.
        Mayo Clin Proc. 1993; 68: 122-127
      1. Yarnold J.R., Owen J.R., Ashton A., et al. Fractionation sensitivity of change in breast appearance after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2002;64 Supplement 1:S25.